RTOG 0518: Randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 4, 2013, Pages 382-386

  Kachnic, L A ^a   Pugh, S L ^b   Tai, P ^c   Smith, M ^d   Gore, E ^e   Shah, A B ^f   Martin, A G ^g   Kim, H E ^h   Nabid, A ⁱ   Lawton, C A F ^c,e  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f York Cancer Center   (United States)

^g UNIVERSITÉ LAVAL   (Canada)

^h WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Androgen deprivation therapy; Bone fractures; Osteoporosis; Radiation therapy

Indexed keywords

CALCIUM; VITAMIN D; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE DENSITY; CANCER RADIOTHERAPY; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMUR NECK FRACTURE; FOLLOW UP; HIP FRACTURE; HUMAN; LUMBAR SPINE; MALE; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPINE FRACTURE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OSTEOPOROSIS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84887613817     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.35     Document Type: Article

References (20)

1. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937-946.
2. Bruder JM, Ma JZ, Basler JW, Welch MD. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 2006; 67: 152-155.
3. Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004; 101: 541-549.
4. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012.
5. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis 1974; 27: 365-375.
6. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
7. Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2012; 15: 36-44.
8. Taxel P, Dowsett R, Richter L, Fall P, Klepinger A, Albertsen P. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int 2010; 106: 1473-1476.
9. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146: 416-424.
10. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004; 100: 892-899.
11. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis)Washington, DC: National Osteoporosis Foundation, 2008.
12. Qaseem A, Snow V, Shekelle P, Hopkins Jr. R, Forciea MA, Owens DK. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 148: 680-684.
13. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int 2008; 19: 1395-1408.
14. Brown JP, Josse RG 2002Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167(10 Suppl): S1-34.
15. Cheung AM, Detsky AS. Osteoporosis and fractures: missing the bridge? JAMA 2008; 299: 1468-1470.
16. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S et al. 2010Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182: 1864-1873.
17. World Health Organization. FRAX WHO Fracture Risk Assessment ToolWorld Health Organization 2012, Available at: www.shef.ac.uk/FRAX/. Accessed 6 October 2013.
18. Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol 2010; 183: 2200-2205.
19. Osteoporosis Canada. Available at www.osteoporosis.calast. Accessed September 2012.
20. Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012; 367: 1714-1723.